The content on this site is intended for healthcare professionals only
Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53 per cent compared with women who took a placebo, according to a study presented at SABCS 2103.
The results of the IBIS II trial could offer a new option for preventing breast cancer in high risk post-menopausal women which is more effective than tamoxifen and has fewer side-effects.
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Genomic testing: Awareness and effective communication between healthcare professionals and patients
OncoAlert Round Up for August 25th - 31st, 2023
Nigeria solidarity support fund and the annual youth engagement campaign on HPV
OncoAlert round up July 28th to August 3rd, 2023
